V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 290005356 | 290003906 | 1.74 | 83.2 | Curative (C) | 2014-01-05 | 2014-01-21 | Doxorubicin + Ifosfamide | N | N | 290005633 | PLATO TRIAL |
| 290005357 | 290003907 | 1.62 | 0 | Palliative (P) | 2017-05-03 | 2017-05-03 | Cisplatin + Docetaxel +Fluorouracil | 02 | N | 290005765 | EOX |
| 290005358 | 290003907 | 1.6 | null | Neo-adjuvant (N) | 2016-12-26 | 2017-01-10 | Enzalutamide | N | Y | 290005765 | ECF |
| 290005359 | 290003908 | 1.61 | null | Curative (C) | 2018-03-04 | 2018-03-22 | CETUXIMAB + CISPLATIN + FU | N | N | 290006039 | EOX |
| 290005360 | 290003909 | 1.71 | 55.4 | Neo-adjuvant (N) | 2015-12-20 | 2016-01-03 | LANREOTIDE | N | N | 290006438 | MCX |
| 290005361 | 290003909 | 1.69 | null | Adjuvant (A) | 2016-09-12 | 2016-09-16 | Cetuximab 14 day | N | Y | 290006438 | CISPLATIN + GEMCITABINE |
| 290005362 | 290003909 | null | null | Palliative (P) | 2016-03-18 | 2016-03-20 | Bevacizumab + FLUOROURACIL + IRINOTECAN | N | N | 290006438 | EOX |
| 290005363 | 290003910 | null | 45.9 | Palliative (P) | 2013-08-28 | 2013-09-01 | OCTREOTIDE | N | null | 290006785 | CAPECITABINE + CISPLATIN + EPIRUBICIN |
| 290005364 | 290003911 | 1.52 | 39.1 | Palliative (P) | 2016-10-19 | 2016-10-26 | CISPLATIN + FLUOROURACIL | N | N | 290006866 | KESTREL TRIAL |
| 290005365 | 290003911 | 0 | 75.3 | Adjuvant (A) | null | 2016-10-12 | Cisplatin + Etoposide (3 day) | N | N | 290006866 | OCTREOTIDE |
| 290005366 | 290003912 | 1.68 | 53.4 | Palliative (P) | 2018-11-18 | 2018-12-01 | Carboplatin AUC 2 - 5 | N | N | 290007106 | CETUXIMAB + RT |
| 290005367 | 290003913 | 1.9 | null | Not known (9) | 2018-05-22 | 2018-06-13 | CETUXIMAB + RT | N | N | 290007173 | BEVACIZUMAB |
| 290005368 | 290003914 | 1.68 | 84 | Disease modification (D) | 2015-06-23 | 2015-07-20 | Gemcitabine + Capecitabine | N | N | 290007307 | EOX |
| 290005369 | 290003915 | null | 74.1 | Palliative (P) | null | 2015-12-03 | CAPECITABINE + RT | N | N | 290007714 | OCTREOTIDE |
| 290005370 | 290003916 | null | 54.45 | Palliative (P) | 2014-05-11 | 2014-05-18 | Capecitabine 42days + RT | 2 | N | 290007882 | CAPECITABINE + RT |
| 290005371 | 290003917 | 1.56 | 61.4 | Palliative (P) | 2013-03-30 | 2013-04-09 | CETUXIMAB + RT | N | N | 290008136 | CETUXIMAB + IRINOTECAN + MDG |
| 290005372 | 290003917 | 1.63 | 54 | Palliative (P) | null | 2013-05-07 | FLUOROURACIL | N | N | 290008136 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 290005373 | 290003917 | 1.53 | 68.9 | Curative (C) | 2017-09-03 | 2017-09-08 | Trial Unspecified | N | N | 290008136 | OCTREOTIDE |
| 290005374 | 290003918 | 1.57 | 60.6 | Curative (C) | 2014-07-17 | 2014-09-20 | Capecitabine | 02 | N | 290008653 | CETUXIMAB + RT |
| 290005375 | 290006665 | 1.71 | 67.6 | Palliative (P) | 2015-02-02 | 2015-02-06 | Doxorubicin + Olaratumab | Y | N | 290008739 | ECX |
| 290005376 | 290006665 | 1.7 | 61.2 | Adjuvant (A) | 2018-09-13 | 2018-09-29 | OCTREOTIDE | N | null | 290008739 | CISPLATIN + ETOPOSIDE |
| 290005377 | 290003919 | 1.68 | null | Palliative (P) | 2017-12-14 | 2017-12-22 | RCEOP | N | N | 290008847 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 290005378 | 290003920 | 1.6 | null | Palliative (P) | null | 2016-10-05 | Cisplatin + Docetaxel +Fluorouracil | null | null | 290008967 | MCX |
| 290005379 | 290003920 | 1.7 | 62 | Disease modification (D) | 2016-05-26 | 2016-05-28 | BENDAMUSTINE + RITUXIMAB | 02 | N | 290008967 | CAPECITABINE + RT |
| 290005380 | 290003921 | 1.83 | 77.4 | Neo-adjuvant (N) | 2016-01-18 | 2016-02-01 | Cisplatin + Docetaxel +Fluorouracil | N | Y | 290009329 | CARBOPLATIN + DOCETAXEL + FLUOROURACIL |
| 290005382 | 290003922 | null | null | Palliative (P) | 2015-01-14 | 2015-01-14 | Capecitabine | N | N | 290009519 | OCTREOTIDE |
| 290005383 | 290003923 | 1.7 | 84.4 | Palliative (P) | 2014-12-12 | 2014-12-29 | CISPLATIN + FLUOROURACIL | N | N | 290009762 | CISPLATIN + FLUOROURACIL |
| 290005384 | 290003924 | 1.87 | 60.4 | Curative (C) | 2019-01-29 | 2019-05-14 | Capecitabine 42days + RT | 02 | Y | 290009831 | CAPECITABINE + CISPLATIN |
| 290005385 | 290003925 | 1.72 | 80 | Curative (C) | null | 2016-05-27 | Methotrexate High Dose (3g/m2) | N | N | 290009865 | CAPECITABINE |
| 290005386 | 290003926 | 1.63 | 78.1 | Neo-adjuvant (N) | 2017-06-06 | 2017-06-10 | Carboplatin + Etoposide IV 3 day | N | N | 290010012 | GEMCITABINE |
| 290005387 | 290003927 | null | null | Curative (C) | 2017-02-19 | 2017-02-19 | Capecitabine | N | null | 290010161 | CARBOPLATIN |
| 290005388 | 290003927 | 1.81 | 112.7 | Adjuvant (A) | 2018-09-10 | 2018-09-16 | Capecitabine | N | N | 290010161 | CAPECITABINE + RT |
| 290005389 | 290003927 | null | 78.9 | Palliative (P) | 2017-02-26 | 2017-03-07 | Capecitabine | N | N | 290010161 | CAPECITABINE + CISPLATIN |
| 290005390 | 290003928 | 1.64 | 90.8 | Palliative (P) | 2016-07-27 | 2016-08-07 | CISPLATIN + FLUOROURACIL | N | N | 290010604 | GEMCITABINE |
| 290005391 | 290003929 | 1.81 | null | Palliative (P) | 2017-11-20 | 2017-11-20 | CETUXIMAB | null | N | 290010785 | TRIAL |
| 290005392 | 290003929 | 1.56 | 66.4 | Curative (C) | 2018-07-12 | 2018-07-12 | CETUXIMAB + RT | N | null | 290010785 | FLUOROURACIL |
| 290005393 | 290003930 | 1.6 | 98.4 | Curative (C) | 2018-03-16 | 2018-03-21 | CETUXIMAB + RT | N | Y | 290011095 | PLATO TRIAL |
| 290005394 | 290003931 | 0 | 97.2 | Adjuvant (A) | null | 2015-11-10 | OCTREOTIDE | N | Y | 290011395 | CAPECITABINE + RT |
| 290005395 | 290003932 | 1.6 | 37.15 | Adjuvant (A) | 2014-12-20 | 2014-12-20 | CAP + RT | 02 | N | 290011692 | CISPLATIN + FLUOROURACIL |
| 290005396 | 290003933 | 1.73 | 66.1 | Palliative (P) | 2018-01-31 | 2018-02-02 | Bortezomib + CYCLOPHOSPHAMIDE | 02 | null | 290011754 | KESTREL TRIAL |
| 290005397 | 290003934 | 1.73 | 0 | Neo-adjuvant (N) | 2018-11-12 | 2018-11-12 | CETUXIMAB + RT | 2 | N | 290011822 | GEMCARBO |
| 290005398 | 290003935 | 1.78 | 72.3 | null | 2013-12-01 | 2013-12-30 | EOX | 2 | N | 290012266 | CISPLATIN + ETOPOSIDE |
| 290005399 | 290003936 | null | 79.9 | Curative (C) | 2013-12-15 | 2014-01-12 | Gemcitabine + Methylprednisolone | null | N | 290012272 | LANREOTIDE |
| 290005400 | 290003937 | 1.7 | 110.2 | Palliative (P) | 2018-02-14 | 2018-03-06 | CISPLATIN + VINORELBINE | N | N | 290012393 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 290005401 | 290003938 | 1.72 | 74.7 | Curative (C) | 2016-12-20 | 2017-01-11 | Trial Unspecified | N | N | 290012658 | CAPECITABINE |
| 290005402 | 290003939 | 1.63 | 103 | Palliative (P) | 2015-03-23 | 2015-03-27 | FLUOROURACIL | 2 | N | 290012849 | DE-ESCALATE TRIAL |
| 290005403 | 290003939 | 1.67 | 107.9 | Disease modification (D) | 2017-05-16 | 2017-05-16 | Sunitinib | null | N | 290012849 | CAPECITABINE + CISPLATIN |
| 290005404 | 290003940 | 1.7 | 74.3 | Palliative (P) | 2018-10-27 | 2018-10-27 | Trial Unspecified | 2 | N | 290013143 | BEVACIZUMAB + CAPE + OXALIPLATIN |
| 290005405 | 290003941 | 1.57 | null | Curative (C) | 2018-05-16 | 2018-06-10 | LANREOTIDE | 02 | Y | 290013423 | IRINOTECAN + MDG |
| 290005406 | 290003942 | 1.63 | null | null | 2016-11-19 | 2016-11-30 | LANREOTIDE | N | N | 290013492 | CETUXIMAB |